RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression

Wang,Qian; Yu,Wei; Huang,Tao; Zhu,Yan; Huang,Changshan

doi:10.3892/or.2016.5101

RUNX2 promotes hepatocellular carcinoma cell migration and invasion by upregulating MMP9 expression

Authors:
- Qian Wang
- Wei Yu
- Tao Huang
- Yan Zhu
- Changshan Huang
View Affiliations

Affiliations: Department of Hepato-biliary-pancreatic surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Medical Oncology, People's Hospital of Henan Province, Zhengzhou, Henan 450000, P.R. China
Published online on: September 19, 2016 https://doi.org/10.3892/or.2016.5101
Pages: 2777-2784

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Runt-related transcription factor 2 (RUNX2) was first identified as a transcription factor to play an important role in different biological processes of osteoblast and chondrocyte, including differentiation and migration. Recently, RUNX2 has been implicated in promigratory/proinvasive behavior in different human malignancies. In the present study, we demonstrated that the RUNX2 mRNA and protein expression were both increased significantly in HCC tissues and cell lines. High RUNX2 expression was correlated obviously with poor clinicopathological characteristics including multiple tumor nodes, high histological grading, venous infiltration and advanced tumor-node-metastasis (TNM) stage. In addition, we demonstrated that RUNX2 was a prognostic indicator for predicting 5-year overall survival and disease-free survival of HCC patients. Our studies showed that RUXN2 overexpression promoted, while RUNX2 knockdown inhibited HCC cell migration and invasion in vitro. Notably, RUNX2 positively regulated matrix metalloproteinase 9 (MMP9) accumulation in HCC cells. Furthermore, we confirmed that RUNX2 was positively correlated with MMP9 expression in HCC tissues by Pearson correlation analysis. Mechanistically, we demonstrated that MMP9 overexpression increased HCC cell migration and invasion, while MMP9 knockdown reduced HCC cell migration and invasion in vitro. Alteration of MMP9 expression partially abrogated the effects of RUNX2 on HCC cell migration and invasion, which suggests that RUNX2 developed its pro-metastatic biological function by upregulating the expression of MMP9 in HCC cells. In conclusion, our results reveal that RUNX2 promotes HCC cell migration and invasion by MMP9-mediated pathway, and potentially serves as a new prognostic biomarker and in therapeutic strategies for HCC.

View Figures

View References

1	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	Talwalkar JA and Gores GJ: Diagnosis and staging of hepatocellular carcinoma. Gastroenterology. 127(Suppl 1): S126–S132. 2004. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
4	Ito Y: Oncogenic potential of the RUNX gene family: 'overview'. Oncogene. 23:4198–4208. 2004. View Article : Google Scholar : PubMed/NCBI
5	Li J, Hao L, Wu J, Zhang J and Su J: Linarin promotes osteogenic differentiation by activating the BMP-2/RUNX2 pathway via protein kinase A signaling. Int J Mol Med. 37:901–910. 2016.PubMed/NCBI
6	Ozaki T, Nakamura M and Shimozato O: Novel implications of DNA damage response in drug resistance of malignant cancers obtained from the functional interaction between p53 family and RUNX2. Biomolecules. 5:2854–2876. 2015. View Article : Google Scholar : PubMed/NCBI
7	Sugimoto H, Nakamura M, Yoda H, Hiraoka K, Shinohara K, Sang M, Fujiwara K, Shimozato O, Nagase H and Ozaki T: Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Dis. 6:e19142015. View Article : Google Scholar : PubMed/NCBI
8	Wysokinski D, Blasiak J and Pawlowska E: Role of RUNX2 in breast carcinogenesis. Int J Mol Sci. 16:20969–20993. 2015. View Article : Google Scholar : PubMed/NCBI
9	Shrivats AR, McDermott MC, Klimak M, Averick SE, Pan H, Matyjaszewski K, Mishina Y and Hollinger JO: Nanogel-mediated RNAi against Runx2 and Osx inhibits osteogenic differentiation in constitutively active BMPR1A osteoblasts. ACS Biomater Sci Eng. 1:1139–1150. 2015. View Article : Google Scholar
10	Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogita K and Komori T: Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol. 166:85–95. 2004. View Article : Google Scholar : PubMed/NCBI
11	Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, et al: Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene. 29:811–821. 2010. View Article : Google Scholar :
12	Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, Kohn-Gabet AE, Shi Y, Coetzee GA and Frenkel B: Runx2 transcriptome of prostate cancer cells: Insights into invasiveness and bone metastasis. Mol Cancer. 9:2582010. View Article : Google Scholar : PubMed/NCBI
13	Brusgard JL, Choe M, Chumsri S, Renoud K, MacKerell AD Jr, Sudol M and Passaniti A: RUNX2 and TAZ-dependent signaling pathways regulate soluble E-cadherin levels and tumorsphere formation in breast cancer cells. Oncotarget. 6:28132–28150. 2015. View Article : Google Scholar : PubMed/NCBI
14	Sancisi V, Borettini G, Maramotti S, Ragazzi M, Tamagnini I, Nicoli D, Piana S and Ciarrocchi A: Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas. J Clin Endocrinol Metab. 97:E2006–E2015. 2012. View Article : Google Scholar : PubMed/NCBI
15	Mendoza-Villanueva D, Deng W, Lopez-Camacho C and Shore P: The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells. Mol Cancer. 9:1712010. View Article : Google Scholar : PubMed/NCBI
16	Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS and Lian JB: The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol. 25:8581–8591. 2005. View Article : Google Scholar : PubMed/NCBI
17	Selvamurugan N, Kwok S and Partridge NC: Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem. 279:27764–27773. 2004. View Article : Google Scholar : PubMed/NCBI
18	Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH and Ge Y: RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: Role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood. 114:2744–2752. 2009. View Article : Google Scholar : PubMed/NCBI
19	Tandon M, Chen Z, Othman AH and Pratap J: Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis. Oncogene. Jan 25–2016.Epub ahead of print. View Article : Google Scholar
20	Sancisi V, Gandolfi G, Ragazzi M, Nicoli D, Tamagnini I, Piana S and Ciarrocchi A: Cadherin 6 is a new RUNX2 target in TgF-β signalling pathway. PLoS One. 8:e754892013. View Article : Google Scholar
21	van der Deen M, Akech J, Wang T, Fitzgerald TJ, Altieri DC, Languino LR, Lian JB, van Wijnen AJ, Stein JL and Stein GS: The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem. 109:828–837. 2010.PubMed/NCBI
22	Zeng H and Xu X: RUNX2 RNA interference inhibits the invasion of osteosarcoma. Oncol Lett. 9:2455–2458. 2015.PubMed/NCBI
23	Peng B, Zhu H, Klausen C, Ma L, Wang YL and Leung PC: GnRH regulates trophoblast invasion via RUNX2-mediated MMP2/9 expression. Mol Hum Reprod. 22:119–129. 2016. View Article : Google Scholar
24	Cohen-Solal KA, Boregowda RK and Lasfar A: RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 14:1372015. View Article : Google Scholar : PubMed/NCBI
25	Tandon M, Chen Z and Pratap J: Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells. Breast Cancer Res. 16:R162014. View Article : Google Scholar : PubMed/NCBI
26	Niu DF, Kondo T, Nakazawa T, Oishi N, Kawasaki T, Mochizuki K, Yamane T and Katoh R: Transcription factor Runx2 is a regulator of epithelial-mesenchymal transition and invasion in thyroid carcinomas. Lab Invest. 92:1181–1190. 2012. View Article : Google Scholar : PubMed/NCBI
27	Zhang X, Akech J, Browne G, Russell S, Wixted JJ, Stein JL, Stein GS and Lian JB: Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer. 136:1321–1332. 2015. View Article : Google Scholar :
28	Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z and Frenkel B: Regulation of breast cancer metastasis by Runx2 and estrogen signaling: The role of SNAI2. Breast Cancer Res. 13:R1272011. View Article : Google Scholar : PubMed/NCBI
29	Zaidi SK, Sullivan AJ, van Wijnen AJ, Stein JL, Stein GS and Lian JB: Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci USA. 99:8048–8053. 2002. View Article : Google Scholar : PubMed/NCBI